A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)
NCT04840680 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 191
Last updated 2024-07-24
Summary
In this study, people with MM will be treated with ixazomib citrate according to their clinic's standard practice. The main aim of the study is to check for side effects from ixazomib citrate.
Conditions
Interventions
- OTHER
-
No Intervention
This is a non-interventional study.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Study Director · Takeda
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-03-22
- Primary Completion
- 2023-07-06
- Completion
- 2023-08-28
- FDA Drug
- Yes
Countries
- South Korea
Study Locations
More Related Trials
-
Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
NCT03748953 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Real Life Treatment for Multiple Myeloma (MM)
NCT04985643 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of NINLARO® in Chinese Adults With Multiple Myeloma
NCT05013190 ·Status: ACTIVE_NOT_RECRUITING
-
A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone
NCT03433001 ·Status: COMPLETED
-
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
NCT04458831 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy
NCT03416374 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
NCT02312258 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma
NCT00036140 ·Status: COMPLETED ·Phase: PHASE1
-
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT03012880 ·Status: COMPLETED ·Phase: PHASE2
-
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
NCT02206425 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04392648 ·Status: WITHDRAWN ·Phase: PHASE1
-
This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.
NCT05486975 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
NCT03608501 ·Status: WITHDRAWN ·Phase: PHASE2
-
Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM
NCT06205823 ·Status: ACTIVE_NOT_RECRUITING
-
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
NCT04840615 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
NCT03439280 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
NCT05722405 ·Status: RECRUITING ·Phase: PHASE4
-
A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant
NCT02181413 ·Status: COMPLETED ·Phase: PHASE3
-
Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma
NCT00263484 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT05719701 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy
NCT03457142 ·Status: TERMINATED ·Phase: PHASE2
-
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT02101944 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma
NCT02917941 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide
NCT04989140 ·Status: UNKNOWN ·Phase: PHASE4
-
Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma
NCT01645930 ·Status: COMPLETED ·Phase: PHASE1